Exact Sciences sank -27.5% this morning, compared to the S&P 500's day change of 2.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:
-
Exact Sciences has logged a 13.8% 52 week change, compared to 31.9% for the S&P 500
-
EXAS has an average analyst rating of buy and is -35.77% away from its mean target price of $80.72 per share
-
Its trailing earnings per share (EPS) is $-0.95, which brings its trailing Price to Earnings (P/E) ratio to -54.6. The Health Care sector's average P/E ratio is 26.07
-
The company's forward earnings per share (EPS) is $-0.08 and its forward P/E ratio is -648.1
-
The company has a Price to Book (P/B) ratio of 2.99 in contrast to the Health Care sector's average P/B ratio is 3.53
-
The current ratio is currently 2.3, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $31.93 Million and the average free cash flow growth rate is 2.8%
-
Exact Sciences's revenues have an average growth rate of 30.3% with operating expenses growing at 28.3%. The company's current operating margins stand at -8.6%
